PE20021089A1 - Compuestos de triazol como inhibidores de las citoquinas - Google Patents

Compuestos de triazol como inhibidores de las citoquinas

Info

Publication number
PE20021089A1
PE20021089A1 PE2002000364A PE2002000364A PE20021089A1 PE 20021089 A1 PE20021089 A1 PE 20021089A1 PE 2002000364 A PE2002000364 A PE 2002000364A PE 2002000364 A PE2002000364 A PE 2002000364A PE 20021089 A1 PE20021089 A1 PE 20021089A1
Authority
PE
Peru
Prior art keywords
alkenyl
alkyl
triazole
alkinyl
triazole compounds
Prior art date
Application number
PE2002000364A
Other languages
English (en)
Inventor
Benjamin Eric Blass
Michael Philip Clark
Rens John Charles Van
Michael Natchus
Joshua Spector Tullis
Biswanath De
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20021089A1 publication Critical patent/PE20021089A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A COMPUESTOS DE TRIAZOL DE FORMULA I DONDE R1 ES ALQUILO, ALQUENILO, ALQUINILO, HETEROALQUENILO, ENTRE OTROS; m ES 0-5; Q ES EL GRUPO a, b, ENTRE OTROS; R2 ES H, ALQUILO, ALQUENILO, ALQUINILO, HETEROALQUILO, ENTRE OTROS; R2 NO ES NR4R5 CUANTO TANTO Y ES CR2 COMO R3 ES H; R3 ES H, ALQUILO, ALQUENILO, ALQUINILO, HETEROALQUILO, HETEROALQUENILO, ENTRE OTROS; X ES CR2, N; Y ES CR2, N; Z ES CR2, NR3, O, S; A ES H, ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; a ES UN ENLACE INDIVIDUAL; B ES H, ALQUILO, ALQUENILO, ENTRE OTROS; b ES UN ENLACE INDIVIDUAL; R4 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; R5 ES H, ALQUILO, ALQUENILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 4-(4-FLUOROFENIL)-5-PIRIDIN-4-IL-1-(TIOFEN-2-ILCARBONIL)-[1,2,3]TRIAZOL, 4-(4-FLUOROFENIL)-5-PIRIDIN-4-IL-1-METILCARBONIL-[1,2,3]TRIAZOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON INHIBIDORES DE LAS CITOQUINAS Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS
PE2002000364A 2001-04-30 2002-04-30 Compuestos de triazol como inhibidores de las citoquinas PE20021089A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28763901P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
PE20021089A1 true PE20021089A1 (es) 2003-02-18

Family

ID=23103747

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000364A PE20021089A1 (es) 2001-04-30 2002-04-30 Compuestos de triazol como inhibidores de las citoquinas

Country Status (8)

Country Link
US (1) US6727364B2 (es)
EP (1) EP1383759A1 (es)
JP (1) JP2004528351A (es)
CN (1) CN1505625A (es)
AU (1) AU2002305226B2 (es)
CA (1) CA2444499A1 (es)
PE (1) PE20021089A1 (es)
WO (1) WO2002088108A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100566709B1 (ko) * 2001-07-24 2006-04-03 오쓰까 세이야꾸 가부시키가이샤 만성 폐색성 폐질환 치료제의 제조를 위한 티아졸유도체의 용도
AR039241A1 (es) * 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
UA80295C2 (en) * 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
US7745630B2 (en) 2003-12-22 2010-06-29 Justin Stephen Bryans Triazolyl piperidine arginine vasopressin receptor modulators
US7276050B2 (en) * 2004-03-02 2007-10-02 Alan Franklin Trans-scleral drug delivery method and apparatus
WO2007016286A1 (en) 2005-07-28 2007-02-08 Janssen Pharmaceutica N.V. Synthesis of 4/5-pyrimidinylimidazoles via sequential functionalization of 2,4-dichloropyrimidine
US20080152592A1 (en) * 2006-12-21 2008-06-26 Bayer Healthcare Llc Method of therapeutic drug monitoring
US20100210932A1 (en) * 2007-03-20 2010-08-19 Bayer Healthcare Llc Method of analyzing an analyte
SG172301A1 (en) * 2008-12-24 2011-07-28 Bial Portela & Ca Sa Pharmaceutical compounds
WO2011140296A1 (en) * 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
US8466181B2 (en) * 2010-12-10 2013-06-18 Hoffmann-La Roche Inc. 1,2,3-triazole-imidazole compounds
US9108930B2 (en) * 2011-04-06 2015-08-18 The Scripps Research Institute N1- and N2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods
CN103275023B (zh) * 2013-06-08 2015-10-07 浙江工业大学 1-芳基-1,2,3-三氮唑类化合物及其制备和应用
WO2014199164A1 (en) * 2013-06-12 2014-12-18 Ampla Pharmaceuticals, Inc. Diaryl substituted heteroaromatic compounds
CN103751190B (zh) * 2013-11-07 2015-09-09 杭州药明生物技术有限公司 ***类化合物在制备乙醛脱氢酶2激活剂中的应用
PE20180529A1 (es) 2015-05-20 2018-03-19 Amgen Inc Agonistas de triazol del receptor apj
US10385057B2 (en) 2015-11-20 2019-08-20 Lundbeck La Jolla Research Center, Inc. Pyrazole compounds and methods of making and using same
WO2017087854A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
WO2017087863A1 (en) 2015-11-20 2017-05-26 Abide Therapeutics, Inc. Pyrazole compounds and methods of making and using same
US10583137B2 (en) 2015-12-02 2020-03-10 The Scripps Research Institute Triazole DAGLα inhibitors
WO2017192485A1 (en) 2016-05-03 2017-11-09 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
AU2017311691B2 (en) 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
WO2018097944A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
MA46824A (fr) 2016-11-16 2019-09-25 Amgen Inc Composés de triazole substitués par alkyle en tant qu'agonistes du récepteur apj
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
JPWO2018159835A1 (ja) * 2017-03-03 2020-04-09 国立大学法人 東京大学 ストリゴラクトン受容体阻害剤、農業用組成物及びそれらの使用、ストライガ種子の発芽抑制剤、並びにトリアゾールウレア化合物
JOP20190267A1 (ar) 2017-05-23 2019-11-18 Lundbeck La Jolla Research Center Inc مثبطات بيرازول magl
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
EA201992409A1 (ru) 2017-05-23 2020-03-23 Лундбекк Ла-Хойя Рисерч Сентер, Инк. Ингибиторы magl на основе пиразола
CN111344284B (zh) * 2017-09-12 2024-03-12 新加坡科技研究局 用作异戊二烯半胱氨酸羧甲基转移酶抑制剂的化合物
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
CN107879986A (zh) * 2017-12-20 2018-04-06 重庆英斯凯化工有限公司 一种阿伐那非杂质的合成方法
WO2019146773A1 (ja) * 2018-01-25 2019-08-01 株式会社フジモト・コーポレーション チオフェン誘導体およびその用途
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
US11795160B2 (en) 2019-02-22 2023-10-24 Insilico Medicine Ip Limited Kinase inhibitors
US11987572B2 (en) * 2019-06-03 2024-05-21 Regents Of The University Of Minnesota Therapeutic compounds and methods of use thereof
KR102406248B1 (ko) * 2019-12-30 2022-06-07 이화여자대학교 산학협력단 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물
KR102406246B1 (ko) * 2019-12-30 2022-06-07 이화여자대학교 산학협력단 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도
WO2021137665A1 (ko) * 2019-12-30 2021-07-08 이화여자대학교 산학협력단 Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도
US11530199B2 (en) 2021-02-24 2022-12-20 Insilico Medicine Ip Limited Analogs for the treatment of disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2212694A1 (de) 1972-03-16 1973-09-20 Hoechst Ag 1,2,3-triazolderivate und verfahren zu ihrer herstellung
EP0727998B1 (en) 1993-11-08 2004-01-21 Smithkline Beecham Corporation Oxazoles for treating cytokine mediated diseases
ES2239357T3 (es) 1996-06-10 2005-09-16 MERCK & CO., INC. Imidazoles sustituidos que tienen actividad inhibidora de citoquinas.
JP2002515915A (ja) 1997-06-30 2002-05-28 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 炎症性疾患の治療で有用な２−置換イミダゾール類
JP2003525201A (ja) 1998-08-20 2003-08-26 スミスクライン・ビーチャム・コーポレイション 新規な置換トリアゾール化合物
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
WO2001012621A1 (en) 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
EP1202733B1 (en) 1999-08-12 2005-10-05 Pharmacia Italia S.p.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
US6962936B2 (en) * 2001-04-27 2005-11-08 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
US6787555B2 (en) * 2001-04-30 2004-09-07 The Procter & Gamble Company Triazole compounds useful in treating diseases associated with unwanted cytokine activity

Also Published As

Publication number Publication date
CA2444499A1 (en) 2002-11-07
AU2002305226B2 (en) 2006-02-02
CN1505625A (zh) 2004-06-16
US20030013712A1 (en) 2003-01-16
EP1383759A1 (en) 2004-01-28
JP2004528351A (ja) 2004-09-16
WO2002088108A1 (en) 2002-11-07
US6727364B2 (en) 2004-04-27

Similar Documents

Publication Publication Date Title
PE20021089A1 (es) Compuestos de triazol como inhibidores de las citoquinas
PE20040590A1 (es) Composiciones de pirrolotriazina anilina como inhibidores de cinasa
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
EA200501617A1 (ru) Новые гетероциклические соединения, применяемые для лечения нарушений аллергической или воспалительной природы: способы синтеза и содержащие их фармацевтические составы
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
PA8495101A1 (es) Derivados de 13-metileritromicina
EA200600225A1 (ru) Производные пиперазина для лечения вич инфекций
ATE338461T1 (de) Pyrazolpyrimidinfungizide
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
DE60211539D1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
SE0104250D0 (sv) Heterocyclic compounds
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
AR022019A1 (es) Un compuesto de imidazol y las composiciones farmaceuticas que lo contienen
ATE372995T1 (de) Benzo(b)(1,4)dioxepinderivate
PT992509E (pt) Novos derivados macrolidos
DE602004031759D1 (de) 1,2,3-triazolamidderivate als inhibitoren der cytokinproduktion
EA200500690A1 (ru) Новые соединения пиридопиримидинона, способ их получения и фармацевтические композиции, которые их содержат
EA200301203A1 (ru) Новые соединения и композиции как ингибиторы катепсина
ATE369348T1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie
SE0203303D0 (sv) Novel Compounds
MXPA05014068A (es) Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina.
MXPA04007048A (es) Derivados de amidoacetonitrilo.

Legal Events

Date Code Title Description
FD Application declared void or lapsed